CPC A61K 31/337 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1075 (2013.01); A61K 9/1641 (2013.01); A61K 9/5138 (2013.01); A61K 9/5146 (2013.01); A61K 9/5192 (2013.01); A61K 47/60 (2017.08); A61P 35/04 (2018.01); B82Y 5/00 (2013.01)] | 7 Claims |
1. A method for treatment of cancer in a subject, the method comprising intraperitoneally injecting the subject with a poly (alkyl cyanoacrylate) nanoparticle, the nanoparticle comprising 6 to 20 wt % cabazitaxel based on the total weight of the nanoparticle and having a size of 10 to 500 nanometers, wherein the nanoparticle does not include a targeting moiety, wherein the cabazitaxel is encapsulated by the nanoparticle, and wherein the nanoparticle is administered to the subject in an amount sufficient to treat the cancer in the subject,
wherein the cancer is peritoneal carcinomatosis originating from ovarian cancer, colorectal carcinoma, cervical cancer, breast cancer, colon cancer, or prostate cancer, or is pseudomyxoma peritonei, and
wherein the poly(alkyl cyanoacrylate) comprises a cyanoacrylate having a 2-ethyl butyl (EBCA) alkyl chain.
|